LLY250103P570000
- 0.00
- 0.000.00%
Eli Lilly and Co Newsroom
These Stocks Are Expected to See at Least 25% Revenue Growth in 2025 – Wolfe
FDA Issues Draft Guidance on Developing Weight Loss Drugs
Citi Says 'Buy' These Stocks in '25; SA Quant Ratings Says Maybe Not
Eli Lilly's Options: A Look at What the Big Money Is Thinking
Express News | Refile-Buzz-Obesity Drugs, M&a Among Key Pharma Drivers for 2025, Berenberg Says
Morgan Stanley Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,146
Express News | Remedium Lifecare - Calls Media Reports Claiming Co Got Order From Eli Lilly Speculative, Unfounded
Lilly to Participate in J.P. Morgan Healthcare Conference
FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development
Healthcare Sector's 2024 Gainers and Losers: Intuitive Surgical, Boston Scientific Tops Chart
Is Eli Lilly and Company (NYSE:LLY) Among Israel Englander's Top Stock Picks Heading Into 2025?
J.P. Morgan Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
Israel Englander's Millennium Management Dumps Nvidia, Loads Up On Broadcom — Here's What The $70 Billion Hedge Fund Sees
Eli Lilly's (NYSE:LLY) Dividend Will Be Increased To $1.50
Novo Nordisk Seeks to Block Compounded Victoza
Smart Money Is Betting Big In LLY Options
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer
Jim Cramer Says Lazard Is 'Really Inexpensive,' Recommends Buying This Tech Stock
Eli Lilly and Company (LLY) Is Attracting Investor Attention: Here Is What You Should Know
Eli Lilly Joins FDA Lawsuit Over Compounded Obesity Drugs, Seeks 'Swift End' And 'To Protect Its Interests'